U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886516) titled 'Apixaban in Thrombocytopenia' on March 14.
Brief Summary: This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes.
The name of the study drug involved in this study is:
-Apixiban (a type of anticoagulant)
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Deep Vein Thrombosis
Pulmonary Embolism and Thrombosis
T...